ADVERTISEMENT
Mankind Pharma Q4 Review: Miss On Operating Performance, Dolat Capital Maintains 'Add' But Cuts Target Price
Dolat Capital downgrades its FY26E/FY27E EPS estimates by 4.6%/3.1%, assuming higher opex, interest and amortization costs and maintain ‘Accumulate’ rating on Mankind Pharma.
22 May 2025, 10:38 AM IST 
Mankind Pharma achieved strong growth of 77% YoY in modern trade and ecommerce channels.(Photo Source: Company website)
Mankind’s domestic formulation revenues grew by 18.4% YoY in Q4 FY25, driven by BSV consolidation and outperformance in chronic therapies, partially offset by regulatory headwinds in certain key acute products and field force optimization initiatives. Ex BSV, domestic formulation growth was 10% YoY.
I’m already a Subscriber
To continue reading this storySubscribe to Unlock & Enjoy your
Subscriber-Only benefits
Subscriber-Only benefits
Choose a plan
Renews automatically. Cancel anytime.
As a Subscriber you get
Access to
Stories
Curated
Newsletters
20,000+
Research Reports
Priority Pass
to Special Events
Ad-Lite
Experience
Subscriber-Only
Rewards
NDTV Profit
Exclusive Stories
Full Access to
NDTV Profit App
Access to
Stories20,000+
Research Reports
Ad-Lite
Experience
NDTV Profit
Exclusive Stories
Curated
Newsletters
Priority Pass
to Special Events
Subscriber-Only
Rewards
Full Access to
NDTV Profit App
Still Not convinced ? Know More
